As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb Company - ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...

Vislink Technologies, Inc. ( NASDAQ: VISL) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Mickey Miller - Chief Executive Officer Mike Bond - Chief Financial Officer ...

Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and will ... and the next steps taken by AbbVie will tell ...

Too many of us are dying, presenting with it too late ... The Cancer Equals campaign Greene is supporting was launched by ...

Independent re/insurance broker BMS Group has introduced BMS Bacchus, a stock throughput insurance solution designed to ...

When it comes to Nestle's, which is one of the biggest names in the business, progress in code compliance, the report ...

which was approved in the US in 2019. Novartis isn’t developing either Gilenya or Mayzent for UC, so the indication would give BMS a chance to grow Zeposia in a category without S1P competition ...

Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...